HCV is a RNA virus belonging to the Flaviviridae family of viruses. Its genome consists of a 9.6 kb single stranded (+) RNA which is composed of a 5´-non coding region (NCR), Processing of the polyprotein by ER peptidases and viral proteases generates three structural proteins (core protein C, and the envelope proteins E1 and E2) and seven non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
NS3 has several functions. It serves both as a serine protease, cleaving the downstream polyprotein junctions, and as a RNA helicase/NTPase, involved in the unwinding of double stranded RNA at the cost of NTP . The NS4A polypeptide functions as a cofactor for the NS3 protease, enhancing its activity . NS4A is also responsible for the anchoring of NS3 to the ER membrane.
NS3 is considered to be a very good target for direct acting HCV drugs, since it has a central role in the viral life cycle. Its role in cleaving the junctions between all the downstream proteins of the HCV polyprotein, thus releasing the functional proteins involved in replication, is clearly critical. In addition, the protease is also responsible for down-regulating the innate immune response of the host cell .
ZN2007 structure is the NS3/4A serine protease substrate analogue，and the competitive inhibition of protease NS3/4A. It inhibited the replication of the virus and cured hepatitis C .
ZN2007 chemical structure was shown in the figure, the structure of "Q" is the independent innovation, with independent intellectual property rights. ZN2007 is strong active and low toxicity. The studies of pre-clinical pharmacology studies and toxicology experiments have completed.